This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nangia-Makker, P. Articles by Raz, A. Search for Related Content PubMed PubMed Citation Articles by Nangia-Makker, P. Articles by Raz, A.

Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast Cancers

¹ Tumor Progression and Metastasis, ² Breast Cancer Program, and ³ Protease Program, Karmanos Cancer Institute, Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan

Requests for reprints: Avraham Raz, Division of Basic Research, Karmanos Cancer Institute, Wayne State University School of Medicine, 110 East Warren Avenue, Detroit, MI 48201. Phone: 313-578-4330; Fax: 313-831-7518; E-mail: raza{at}karmanos.org.

Failed therapies directed against matrix metalloproteinases (MMP) in cancer patients may be attributed, in part, to lack of diagnostic tools to differentiate between pro-MMPs and active MMPs, which indicate whether a treatment is efficacious or not. Because galectin-3 is cleavable in vitro by MMPs, we have developed differential antibodies recognizing its cleaved and noncleaved forms and tested their clinical utilization as a surrogate diagnostic marker for the presence of active MMPs in growing breast cancers. Wild-type and cleavage-resistant galectin-3 were constructed and expressed in galectin-3–null human breast carcinoma cells (BT-549). Tumorigenic and angiogenic potential of the clones was studied by injections into nude mice. MMP-2, MMP-9, full-length, and cleaved galectin-3 were localized in the xenografts by immunohistochemical analysis of paraffin-embedded sections using specific antibodies. Activities of MMP-2/9 were corroborated by in situ zymography on frozen tissue sections. Galectin-3 cleavage was shown in vivo by differential antibody staining and colocalized with predicted active MMPs both in mouse xenografts and human breast cancer specimens. In situ zymography validated these results. In addition, BT-549 cells harboring noncleavable galectin-3 showed reduced tumor growth and angiogenesis compared with the wild-type. We conclude that galectin-3 cleavage is an active process during tumor progression and could be used as a simple, rapid, and reliable surrogate marker for the activities of MMPs in growing breast cancers. [Cancer Res 2007;67(24):11760–8]

This article has been cited by other articles:

				Y. Wang, P. Nangia-Makker, L. Tait, V. Balan, V. Hogan, K. J. Pienta, and A. Raz Regulation of Prostate Cancer Progression by Galectin-3 Am. J. Pathol., April 1, 2009; 174(4): 1515 - 1523. [Abstract] [Full Text] [PDF]

				V. Balan, P. Nangia-Makker, A. G. Schwartz, Y. S. Jung, L. Tait, V. Hogan, T. Raz, Y. Wang, Z. Q. Yang, G. S. Wu, et al. Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study Cancer Res., December 15, 2008; 68(24): 10045 - 10050. [Abstract] [Full Text] [PDF]